Current Cancer Drug Targets

Papers
(The H4-Index of Current Cancer Drug Targets is 15. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
Micro-fragmented Fat Inhibits the Progression of Human Mesothelioma Xenografts in Mice89
Immune Checkpoint Inhibitors for Advanced Biliary Tract Cancer44
Development of Chromatin Regulator-related Molecular Subtypes and a Signature to Predict Prognosis and Immunotherapeutic Response in Head and Neck Squamous Cell Carcinoma38
Spinal KCC2 Mediates the Modulation Effect of HDAC2 on Bone Cancer Pain in Rats36
A Review on Patient-derived 3D Micro Cancer Approach for Drug Screen in Personalized Cancer Medicine30
Etiology-based Molecular Characterization of Hepatocellular Carcinoma Reveals SQLE's Contribution to Immunosuppressive Microenvironment29
Progress in Metabolic Studies of Gastric Cancer and Therapeutic Implications27
A Pilot Study of Anlotinib as a Combination Treatment in Advanced Nasopharyngeal Carcinoma27
LMNB1/CDKN1A Signaling Regulates the Cell Cycle and Promotes Hepatocellular Carcinoma Progression26
TBOPP, a DOCK1 Inhibitor, Potentiates Cisplatin Efficacy in Breast Cancer by Regulating Twist-mediated EMT24
Expression, Prognostic Value, and Immune Infiltration of MTHFD Family in Bladder Cancer23
Bioinformatics and Experimental Study Revealed LINC00982/ miR-183-5p/ABCA8 Axis Suppresses LUAD Progression18
Efficacy and Safety of Immunotherapy Combined with Anlotinib as First-Line Treatment in Older NSCLC Patients with PD-L1 Expression<50%18
The Therapeutic Potential of Urolithin A for Cancer Treatment and Prevention16
Knockdown of PRKD2 Enhances Chemotherapy Sensitivity in Cervical Cancer via the TP53/CDKN1A Pathway16
Combined RNAi of CTTN and FGF2 Modulates Cell Migration, Invasion and G1/S Transition of Hepatocellular Carcinoma through Ras/ERK Signaling Pathway15
The Expression of Glutaminases and their Association with Clinicopathological Parameters in the Head and Neck Cancers15
FHOD3 Promotes the Progression of Lung Cancer by Regulating the Caspase-3-Mediated Signaling Pathway15
Silencing HEATR1 Rescues Cisplatin Resistance of Non-small Cell Lung Cancer by Inducing Ferroptosis via the p53/SAT1/ALOX15 Axis15
0.12260103225708